Strides Pharma Science Ltd Share Price Strides Pharma

412.10

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

411.05

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 18-Oct-2019 - -
Quarterly Results This has reference to our letter dated October 19, 2019 relating to intimation of Board Meeting scheduled to be held on Friday, October 25, 2019 to consider and approve the Unaudited Financial Results (Standalone and Consolidated basis) for the quarter and half year ended September 30, 2019. In compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, please find enclosed copies of newspaper advertisements published in Business Standard (English Edition) and Lokmat (Marathi Edition), both dated October 19, 2019. This is for your information and records. (As Per BSE Announcement Dated 22.10.2019) We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2019, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 10:30 hrs and concluded at 11:30 hrs. This is for your information and record. The Board of Directors of the Company in their meeting held today i.e., October 25, 2019 have allotted 3,350 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid up share capital of the Company has increased to Rs. 89,55,28,260/- divided into 8,95,52,826 equity shares of Rs. 10/- each. (As Per BSE Announcement Dated 25.10.2019)
Board Meeting - 20-Sep-2019 - -
The Board of Directors of the Company in their meeting held today i.e., September 20, 2019 has granted 50,000 stock options to eligible employees of the Company under the Strides Employee Stock Option Plan 2016 at Rs. 269.70 per option (exercise price). The shares covered by such options are 50,000 equity shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 12 months from the date of vesting (exercisable in not more than two tranches).
Board Meeting - 23-Jul-2019 - -
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2019 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday, July 29, 2019 to consider and approve inter alia: a) unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2019. b) declaration of Interim Dividend, if any, to the equity shareholders of the Company for the Financial Year 2019-20. Further, as per the provisions of the Companys Code for Prevention of Insider Trading, trading window for designated employees of the Company is closed from Monday, July 1, 2019 to Wednesday, July 31, 2019 (both days inclusive). This is for your kind information and record purposes. We wish to inform you that the Board of Directors at their meeting held today i.e., July 29, 2019, inter alia, have approved the following: An Interim Dividend of Rs. 12/- (Rupees Twelve Only) per equity share of Rs. 10/- each to the shareholders of the Company. Record Date for determining the eligibility of shareholders for payment of interim dividend will be Friday, August 23, 2019. The said Interim Dividend will be paid on or before Tuesday, August 27, 2019. This is for your kind information and record purpose. The Board of Directors of the Company in its meeting held today have approved the Scheme of Amalgamation (Scheme) for merger of Arrow Remedies Private Limited (Arrow Remedies), Fagris Medica Private Limited (Fagris Medica) and Strides Emerging Markets Limited (SEML) with the Company, pursuant to Sections 230 to 232 of the Companies Act, 2013. Arrow Remedies, Fagris Medica and SEML are, direct or indirect, wholly-owned subsidiaries of the Company. The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal, the shareholders and creditors of each of the companies. The disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with relevant circulars is enclosed as Annexure A to this intimation. (As Per BSE Announcement Dated 29.07.2019)
Board Meeting - 04-May-2019 - -
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2019 ,inter alia, to consider and approve We write to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Friday, May 10, 2019 to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2019 and recommendation of dividend, if any, amongst other matters. Further, the Company confirms that as per the Companys Code for Prevention of Insider Trading, the trading window for dealing in the securities of the Company was closed for the Companys Directors/ Officers and Designated Persons of the Company from April 4, 2019 till 48 hours after announcement of financial results, i.e., upto May 12, 2019 (both days inclusive). This is for your kind information and appropriate dissemination. The Board of Directors at their meeting held today i.e., on May 10, 2019, have recommended final dividend of 30% at Rs. 3/- per share for the year ended March 31, 2019. The dividend will be paid within 30 days from the date of Shareholders approval at the ensuing Annual General Meeting of the Company. This is for your information and record. The Board of Directors at their meeting held today i.e., on May 10, 2019, have approved and adopted the Audited Financial Statements along with the Auditors Report for the quarter/ year ended March 31, 2019. In this regard, please find enclosed herewith the following: a) Audited Financial Statements (Standalone and Consolidated) along with Auditors Report for the financial year ended March 31, 2019. b) Press Release tilted Strides announces a strong Q4FY19 performance to exit FY19 on a high The board meeting commenced at 11:30 hrs and concluded at 13:00 hrs. This is for your information and record. The Board of Directors at their meeting held today i.e., on May 10, 2019, have recommended final dividend of 30% at Rs. 3/- per share for the year ended March 31, 2019. The dividend will be paid within 30 days from the date of Shareholders approval at the ensuing Annual General Meeting of the Company. This is for your information and record. Pursuant to recommendation of Nomination & Remuneration Committee, the Board of Directors at their meeting held today i.e., on May 10, 2019, have approved re-appointment of the following Independent Directors of the Company for the second term of 5 years from the date of ensuing Annual General Meeting (AGM), subject to approval of shareholders of the Company: 1) Mr. S Sridhar - DIN: 00004272 2) Ms. Sangita Reddy - DIN: 00006285 This is for your information and record. (As Per BSE Announcement Dated on 10.05.2019)
Board Meeting - 22-Jan-2019 - -
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2019 ,inter alia, to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2018. Further, as per the provisions of the Companys Code for Prevention of Insider Trading, trading window for designated employees of the Company is closed from Tuesday, January 22, 2019 upto Thursday, January 31, 2019 (both days inclusive). We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and nine months ended December 31, 2018, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 11:30 hrs and concluded at 12:30 hrs. This is for your information and record. (As Per BSE Announcement Dated On 29/01/2019)